The positive Fabry disease data and BLA submission represent a key near-term catalyst, but the company's survival hinges on securing substantial additional funding by mid-2026. Traders should monitor upcoming regulatory interactions and potential partnership announcements, particularly around commercialization of ST-920.
Price Chart
Executive Summary
Sangamo Therapeutics reported mixed financial results for 2025, with declining annual revenue and widening net losses, but highlighted significant clinical progress in its Fabry disease gene therapy program, including positive eGFR data and an ongoing rolling BLA submission under FDA Accelerated Approval. The company also advanced its neurology pipeline and raised over $130 million in funding since 2025, though it expects to need additional capital to continue operations beyond Q3 2026.
Key Financial Metrics
Key Facts
- Positive topline results from the STAAR study in Fabry disease showed a mean annualized eGFR slope improvement of 1.965 mL/min/1.73m²/year at 52 weeks across 32 patients.
- Rolling BLA submission for ST-920 (isaralgagene civaparvovec) is ongoing, with completion expected as early as summer 2026, contingent on securing additional funding.
- Annual revenue declined from $57.8M in 2024 to $39.6M in 2025, primarily due to a $49.9M decrease in revenue from Genentech, partially offset by $18.4M from Lilly capsid licensing.
- Net loss widened to $122.9M in 2025 from $97.9M in 2024, despite lower non-GAAP operating expenses ($134.5M vs $138.8M).
- Cash and cash equivalents dropped from $41.9M in 2024 to $20.9M in 2025; management states current cash will fund operations into Q3 2026, subject to additional financing.
Financial Impact
Revenue down $18.2M year-over-year; net loss increased by $25M; cash reserves down by $21M. 2026 guidance projects $120M–$140M in GAAP operating expenses.
Risk Factors
- High risk of dilution or bankruptcy if additional funding is not secured in the near term.
- FDA may not accept eGFR slope as a surrogate endpoint for Accelerated Approval.
- Reliance on partnerships for revenue increases execution and counterparty risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3264991 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 1, 2026 13w ago | 8-K | $0.0740 awaiting T+20 | awaiting T+20 | — | — |
Apr 29, 2026 22w ago | 8-K | $0.1300 $0.2000 | ▼ −53.85% | ▼ −48.39% | — |
Apr 21, 2026 23w ago | Insider Cluster | $0.2600 $0.1300 | ▼ −50.00% | ▼ −54.91% | — |
Mar 30, 2026 26w ago | Press Release | $0.2500 $0.1387 | ▼ −44.52% | ▼ −53.94% | — |
Mar 19, 2026 28w ago | Press Release | $0.3300 $0.2700 | ▼ −18.18% | ▼ −27.50% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access